Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism by Vincent, Isabel M. et al.
  
 
 
 
 
Vincent, I. M., Weidt, S., Rivas, L., Burgess, K., Smith, T. K., and 
Ouellette, M. (2014) Untargeted metabolomic analysis of miltefosine action 
in Leishmania infantum reveals changes to the internal lipid metabolism. 
International Journal for Parasitology: Drugs and Drug Resistance, 4(1), pp. 
20-27. 
 
 
Copyright © 2013 The Authors. 
 
 
 
 
This work is made available under the Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 Unported License (CC BY-NC-ND 3.0).  
 
Version: Published 
 
 
http://eprints.gla.ac.uk/105295/ 
 
 
 
 
 
 
Deposited on:  22 April 2015. 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of 
Glasgow http://eprints.gla.ac.uk 
International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 20–27Contents lists available at ScienceDirect
International Journal for Parasitology:
Drugs and Drug Resistance
journal homepage: www.elsevier .com/ locate/ i jpddrUntargeted metabolomic analysis of miltefosine action in Leishmania
infantum reveals changes to the internal lipid metabolism2211-3207  2013 The Authors. Published by Elsevier Ltd.
http://dx.doi.org/10.1016/j.ijpddr.2013.11.002
⇑ Corresponding author. Address: Centre de Recherche en Infectiologie du CHUL,
2705, boul. Laurier, Québec G1V 4G2, Canada. Tel.: +1 (418) 654 2705; fax: +1 (418)
654 2715.
E-mail address: Marc.Ouellette@crchul.ulaval.ca (M. Ouellette).
Open access under CC BY-NC-ND license.Isabel M. Vincent a, Stefan Weidt b, Luis Rivas c, Karl Burgess b, Terry K. Smith d, Marc Ouellette a,⇑
aCentre de Recherche en Infectiologie, Université Laval, Québec, Canada
bGlasgow Polyomics Facility, University of Glasgow, Glasgow, UK
cCentro de Investigaciones Biológicas (CSIC), Madrid, Spain
d Schools of Biology & Chemistry, Biomedical Sciences Research Complex (BSRC), The North Haugh, The University, St. Andrews, UK
a r t i c l e i n f o a b s t r a c tArticle history:
Received 6 September 2013
Received in revised form 8 November 2013
Accepted 14 November 2013
Available online 5 December 2013
Keywords:
Miltefosine
Leishmania
Metabolomics
Mode of actionThere are many theories as to the mode of action of miltefosine against Leishmania including alterations
to the membrane lipid content, induction of apoptosis and modulation of macrophage responses. Here we
perform untargeted metabolomics to elucidate the metabolic changes involved in miltefosine action.
Over 800 metabolites were detected, 10% of which were significantly altered after 3.75 h. Many of the
changes related to an increase in alkane fragment and sugar release. Fragment release is synchronised
with reactive oxygen species production, but native membrane phospholipids remain intact. Signs of
DNA damage were also detected as were changes to the levels of some thiols and polyamines. After
5 h of miltefosine treatment the cells showed depleted levels of most metabolites, indicating that the
cells’ outer membrane integrity had become compromised and internal metabolites were escaping upon
cell death. In miltefosine resistant cells, the drug was not internalised and the changes to the internal
metabolite levels were not seen. In contrast, cells resistant to antimony (SbIII) had similar corresponding
alterations to the levels of internal metabolites as wild-type cells. A detailed knowledge of the mode of
action of miltefosine will be important to inform the design of combination therapies to combat leish-
maniasis, something that the research community should be prioritising in the coming years.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The species of the Leishmania genus of protozoan parasites are
responsible for significant morbidity and mortality in 88 countries
in Africa, the Middle East, Asia, Southern Europe and South and
Central America (WHO, 2010). Treatments for the complex of dis-
eases caused by Leishmania vary depending on the infective species
and the geographical location of infection. The compounds range
between the ancient and toxic antimonial therapies to the newer,
more targeted amphotericin B liposomal formulations (Croft
et al., 2006). The alkylphosphocholine drug miltefosine, is the first
and only orally-available leishmanicide, available after having first
being developed as an antineoplastic agent. It has been licensed for
10 years in India for the treatment of visceral leishmaniasis and
can also be used to treat cutaneous disease (Dorlo et al., 2012).Resistance in the field has not yet been reported, but it is readily
selected for in the laboratory (Pérez-Victoria et al., 2006a; Seiferta
et al., 2007; Choudhurya et al., 2008; Coelho et al., 2012), and high-
er drug concentrations may start to be required to prevent parasite
recrudescence in the field.
The mechanism of action (MOA) of miltefosine has been the
subject of some debate, which may indicate the presence of multi-
ple targets, or may be due to the different experimental designs
and analyses carried out. Traditionally, miltefosine has been con-
sidered as an inhibitor of protein kinase B (Akt or PKB) in humans,
which is part of a signalling pathway involved in the induction of
apoptosis (Ruiter et al., 2003). Similar pathways have not been
seen in Leishmania, however, nor has binding of miltefosine to a
Leishmania analogue of Akt. Other theories for the miltefosine
MOA in Leishmania include: alterations to the membrane lipid con-
tent and modulation of macrophage responses, although clearly
the latter would not be involved in insect stage (promastigote) re-
sponses to the drug.
Lux et al. (1996) suggested that ether lipid metabolism, GPI an-
chor biosynthesis and signal transduction were putative targets of
miltefosine. Further studies analysed the effects of miltefosine on
prepared lipid monolayers indicating interactions leading
miltefosine to be inserted into the monolayers (Rakotomanga
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promastigotes leading to an increased phosphatidylethanolamine
and lysophosphatidylcholine content (Rakotomanga et al., 2007).
A more recent analysis of membrane phospholipids by liquid chro-
matography mass spectrometry provided a more detailed analysis
of the lipid species altered after miltefosine administration and re-
vealed a more complicated picture with different classes of lipids
showing changes to some, but not all group members (Imbert
et al., 2012). Miltefosine has also been shown to interfere with cho-
line transport (Zufferey and Mamoun, 2002), which may account
for some of the changes to the phospholipid content of the
membrane.
The apoptosis theory of miltefosine MOA was conceived after
the observation of some of the classical signs of apoptosis such
as an increase in reactive oxygen species, nuclear condensation,
DNA fragmentation and a loss of membrane potential (Moreira
et al., 2011). These signs, however, could also be due to non-regu-
lated cell death, which was recently reviewed (Proto et al., 2013).
Resistance to miltefosine in Leishmania points to a transporter
defect, with two transporters implicated (miltefosine transporter
(MT)) coupled to its regulatory subunit ROS3 (Pérez-Victoria
et al., 2006b) for inward translocation and an ABC transporter to
expel the drug (Pérez-Victoria et al., 2006a). The fact that the drug
is internalised means that it would be particularly useful to study
changes to the internal metabolite repertoire after the administra-
tion of miltefosine. The alterations to the membrane lipid comple-
ment may then be explained by an internal metabolic or catabolic
mechanism and this should not happen in resistant cells, in which
miltefosine is not translocatable.
We present here our comparison of the internal metabolite rep-
ertoire between wild-type promastigotes treated with miltefosine
and two resistant lines: a miltefosine resistant line, in which we do
not expect to see metabolic changes and an antimony (SbIII) resis-
tant line, to ensure the specificity of changes observed.2. Materials and methods
2.1. Culture and resistance selection
The Leishmania infantum JPCM5 promastigote cell line was used
as the wild-type parent line from which the derived lines MF200
and SbIII2000.2 were selected by a stepwise increase in drug pres-
sure and were resistant to 200 lM miltefosine (Cayman Chemical,
Ann Harbor, USA) or 2 mM SbIII (Potassium antimonyl tartrate tri-
hydrate, Aldrich, USA) respectively. The wild-type IC50s for miltefo-
sine and SbIII are 15 lM and 70 lM respectively (data not shown).
Cells were not clonal and grew at a rate similar to wild-type. Cells
were maintained in medium 199 (M199; Gibco) supplemented
with 10% heat-inactivated foetal bovine serum and 10 lg/ml hae-
min at 28 C and either 200 lM of miltefosine of 2 mM SbIII.
IC90s were taken by serial dilution of drug in 96 well transpar-
ent plates before addition of cells at a final concentration of
2.5  106/ml and incubation at 28 C with shaking for 72 h. The
optical density of each well in the plate was read at a wavelength
of 600 nm and analysed using Graphpad Prism5 using non-linear
regression analysis.2.2. Metabolomics
Cells were inoculated at 5  106/ml in M199 from a log-phase
culture and miltefosine was added at 20.6 lM (IC90). Samples were
taken at the time taken for 50% of wild-type cells to die (5 h) as
well as time points (0, 1.25, 2.5 and 3.75 h) up to 5 h. All samples
were taken in triplicate from independent cultures. Cell metabo-
lism in 4  107 cells was quenched by rapid cooling to 4 C in adry ice-ethanol bath before centrifugation at 1250g for 5 min to re-
move medium. Residual medium was removed by washing in 4 C
HEPES–NaCl and cells were lysed and proteins precipitated by
shaking in 200 lL 4 C chloroform:methanol:water (1:3:1) plus
standards (theophylline, 5-fluorouridine, N-methyl glucamine,
canavanine and piperazine, all at 1 lM) for 1 h. Protein precipitate
was removed by centrifugation and a 10 lL aliquot of the superna-
tant was injected onto a 150 mm  4.6 mm 5 lm 200 Å ZIC-HILIC
HPLC column (SeaQuant, Merck). The column was coupled to an
Orbitrap Exactive (Thermo) and masses and retention times were
detected using a previously published method (Vincent et al.,
2012). Data analysis was performed using mzMatch (Scheltema
et al., 2011) and Excel (Microsoft) with a VBS macro-based package
called IDEOM (Creek et al., 2012) for further filtering and metabo-
lite annotation. The independent biological replicates were taken
for each time point from separate cultures on different days. These
were run on the mass spectrometer in the same run.
Five internal standards were used to correct for mass drift and a
further mixture of 143 standards was used to create the retention
time calculator in IDEOM, allowing accurate mass and retention
time identification as well as metabolite validation. Masses were
filtered through mzMatch keeping those that were reproducible
across all three biological replicates at each time point, had relative
standard deviations below 0.5 and had intensities above 3000.
Metabolites were further filtered in IDEOM (version 13) to have a
retention time error of below 35% and mass errors below three
parts per million (ppm) for those metabolites with predicted reten-
tion times of below 5% and three ppm for metabolites with a stan-
dard. Partial least squares analysis was performed using
Metaboanalyst after pre-processing in IDEOM and data filtering
using the relative standard deviation (http://www.metaboanalyst.
ca/).2.3. Miltefosine uptake
Log phase cells were washed in HEPES–NaCl and re-suspended
to 4  108/ml. 100 lL of the cell suspension was added to 100 lL of
5 lM MT-11C-BODIPY (11-(40,40-Difluoro-10,30,50,70-tetramethyl-
40-bora-30a,40a-diaza-s-indacen-20-yl) undecyl-phosphocholine)
(Hornillos et al., 2008) in HEPES–NaCl and tubes were left in the
dark at room temperature for varying lengths of time before wash-
ing twice in 1 ml HEPES–NaCl. Cells were re-suspended to 200 lL
in HEPES–NaCl and the fluorescence was read (Victor2, Perkin El-
mer, Turku, Finland) at excitation 485 nm, emission 535 nm for
1 s per well. The fluorescence of 5 lM MT-11C-BODIPY was also
read and this figure was used to calculate the moles of internalised
miltefosine. At least three biological replicates were taken for each
time point.2.4. ROS measurements
4  107 cells were taken from a log phase culture at 5  106 -
cells/ml at time points 0, 1.25, 2.5, 3.75 and 5 h after 20.6 lM
miltefosine addition, 5 h being the point at which 50% of wild-
type cells are dead compared to untreated cells. Cells were
washed twice in 1 mL HEPES–NaCl then re-suspended in 500 lL
HEPES–NaCl containing 40 nM DCFDA (Dichlorofluorescein diace-
tate, a dye that measures total ROS in live cells) (Invitrogen, Bur-
lington, Ontario, Canada). Cells were left in the dark for 30 min
before being washed twice in HEPES–NaCl, and re-suspended in
500 lL. 200 lL of the cell suspension was read with a Victor2
fluorometer (Perkin Elmer, Turku) at 485 nm excitation and
535 nm emission. Three independent biological replicates were
taken for each time point.
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PCR products of the miltefosine transporter amplified with the
primers MT_F 50ATGCCCAACCAACCG30 and MT_R 50TCACAGCTTTC-
CACC30 were ligated to pGEM-T easy (Promega) and sequenced
using an in-house platform.
2.6. Microscopy
Cells were fixed in methanol and Giemsa stained using Diff-
Quik (Baxter) reagents. The microscope (Nikon Eclipse TE300)
was used at 100 magnification using oil immersion. Image Pro
(Media Cybernetics) was used to prepare the images.
2.7. Lipid analysis
Total lipids were extracted using a modified Bligh and Dyer
method (Bligh and Dyer, 1959). Briefly, cells were washed with
PBS, suspended in 100 ll PBS and transferred to a glass tube,
375 lL of 1:2 (v/v) chloroform:methanol were added and vortexed.
The sample was agitated vigorously for a further 10–15 min. The
sample was made biphasic by the addition of 125 lL chloroform,
followed by vortexing and subsequently the addition of 125 lL of
H2O. The mixture was then vortexed again and centrifuged at
1000g at room temperature for 5 min. The lower phase was trans-
ferred to a new glass vial and dried under nitrogen and stored in
the fridge.
Total lipid extracts were dissolved in 15 lL of 1:2 (v/v) chloro-
form:methanol and 15 lL of acetonitrile:iso-propanol:water
(6:7:2) and analysed with a Absceix 4000 QTrap, a triple quadru-
pole mass spectrometer equipped with a nanoelectrospray source.
Samples were delivered using a Nanomate interface in direct
infusion mode (125 nl/min). The lipid extracts were analysed in
both positive and negative ion modes using a capillary voltage of
1.25 kV. MS/MS scanning (daughter, precursor and neutral loss
scans) were performed using nitrogen as the collision gas with col-
lision energies between 35 and 90 V. Each spectrum encompasses
at least 50 repetitive scans.
Tandem mass spectra (MS/MS) were obtained with collision
energies as follows: 35–45 V, PC/SM in positive ion mode, par-
ent-ion scanning of m/z 184; 35–55 V, PI/IPC in negative ion
mode, parent-ion scanning of m/z 241; 35–65 V, PE in negative
ion mode, parent-ion scanning of m/z 196; 20–35 V, PS in nega-
tive ion mode, neutral loss scanning of m/z 87; and 40–90 V, for
all glycerophospholipids (including PA, PG and cardiolipin) de-
tected by precursor scanning for m/z 153 in negative ion mode.
MS/MS daughter ion scanning was performed with collision ener-
gies between 35 and 90 V. Assignment of phospholipid species is
based upon a combination of survey, daughter, precursor and
neutral loss scans, as well previous assignments (Richmond
et al., 2010; Williams et al., 2012). The identity of phospholipid
peaks was verified using the LIPID MAPS: Nature Lipidomics
Gateway (www.lipidmaps.org).
2.8. Thin layer chromatography
2  108 log-phase promastigotes were washed in HEPES–NaCl
and resuspended at 4  108/ml in HEPES–NaCl. BODIPY-miltefo-
sine was added to a final concentration of 10.4 lM and these sam-
ples were incubated for 5 h in the dark at room temperature.
Samples were washed and neutral lipids were extracted by resus-
pending in 1 mL 1:0.5:0.4 methanol:chloroform:water. These were
incubated for 1 h, with regular vortexing before centrifuging for
20 min at 3000 RPM. The supernatant was taken and 1 mL
1:0.5:0.4 methanol:chloroform:water was added to the pellet, this
was extracted again for 1 h at room temperature with regularvortexing then centrifuged again. The supernatants were pooled
and 1:1 chloroform:water was added until the solution became bi-
phasic. The samples were centrifuged for 30 min at 3000 RPM and
the organic phase was taken and evaporated under nitrogen. Lipids
were dissolved in 50 lL methanol and spotted onto TLC silica gel
60 F254 paper (Merck). Extracts were run in 15:13:12:40:8 ace-
tone:methanol:acetic acid:chloroform:water for approximately
2 h and read under UV light.3. Results
3.1. Metabolomics analyses and detection of miltefosine
To ensure that metabolomics samples were collected at biolog-
ically relevant drug concentrations and time points, the IC90 of mil-
tefosine was calculated on our wild-type cell line of L. infantum
JPCM5 over 72 h (Fig. 1a). The IC90 at 72 h (20.6 lM) was then used
to determine the time taken for cells to become 50% inhibited
according to their cell number compared to untreated cells
(Fig. 1b). This was taken as the end point of our experiment with
time points taken up to this point. There was significant resistance
(p = 0.001 from ANOVA with Dunnett’s post hoc test) in the mil-
tefosine resistant line, MF200 (miltefosine IC90: 239 lM) and a
small, but not significant resistance in the SbIII resistant line,
SbIII2000.2 (miltefosine IC90: 37 lM) (Fig. 1a). Leishmania cells
treated with miltefosine produce reactive oxygen species (ROS)
(Moreira et al., 2011; Getachew and Gedamu, 2012). To discrimi-
nate between miltefosine-induced and ROS-induced metabolite
changes, we tested for ROS production during miltefosine treat-
ment. A gradual miltefosine-induced ROS production was observed
in wild-type cells, but not in the MF200 line (Fig. 1c). The SbIII
resistant line produced slightly less ROS (Fig. 1c) when challenged
with miltefosine, although this was not significantly different to
the wild-type miltefosine-induced ROS level.
After processing through mzMatch and IDEOM, 876 feature
annotations (assigned to putative metabolites) were identified in
the metabolite extracts (Supplementary Table 1). Partial least
squares analysis reveals that 81.1% of the separation between the
samples groups is in the first and second components (Supplemen-
tary Fig. 1). The 143 internal standards enabled 16% of the metab-
olome to be validated and an accurate prediction based on mass
and retention time for the other metabolites (noted as putative).
A confidence level for each identification is provided in Supple-
mentary Table 1, and confidence levels below five were excluded
from further analyses.
The monoisotopic mass of miltefosine is 407.3164 (based on the
empirical formula) and since it is zwitterionic it should be easily
detectable in both positive and negative ionisationmodes, however
the metabolite was not in IDEOM’s internal database and therefore
not automatically identified. Upon searching the raw data for the
mass of miltefosine, it was observed that the miltefosine was inter-
nalised in the wild-type cell line, but to a much lesser extent in the
MF200 resistant cell line (Fig. 2a). The wild-type line also showed a
significant decrease in miltefosine accumulation at the final time
point. This correlates with a decrease of the majority of metabolites
at this time point, as discussed later. Surprisingly, there was less
miltefosine accumulation in the SbIII2000.2 line, as determined
by LC–MS at 2.5 and 3.75 h (Fig. 2a), although this difference was
not significant (p > 0.05 in a Student’s t-test). As LC–MS metabolo-
mics analyses are semi-quantitative, we chose to verify these mil-
tefosine accumulation results using a fluorescent miltefosine
derivative (MT-11C-BODIPY) (Hornillos et al., 2008). While this
fluorescent analogue was transported into the wild-type cells, the
same reduced uptake phenomenon was seen in the miltefosine
resistant cell line (Fig. 2b). A 2.2-fold difference in the amount of
0 
0.5
1 
1.5
2 
2.5
3 
3.5
0 1 2 3 4 5 6 
R
el
at
iv
e 
R
O
S 
Time (hours)
a
b 
c
Untreated Treated
d 
JPCM5
SbIII2000.2
MF200
0 
2 
4 
6 
8 
10
12
0 2 4 6 8 
C
el
l n
um
be
r 
(1
06
pe
r 
m
l)
Time (hours)
-7 -6 -5 -4 -3 -2
0.0
0.5
1.0
1.5
MF Log 10 (M)
N
or
m
al
is
ed
 O
D
* 
* * 
Fig. 1. Miltefosine effects on cell growth, morphology and reactive oxygen species production. (a) The IC90 of miltefosine was measured in JPCM5 (20.6 lM), MF200 (239 lM)
and SbIII2000.2 (37.3 lM) cell lines over 72 h. An average of at least three independent biological replicates is shown, with error bars depicting the standard error of the
mean. (b) Cell counts during miltefosine treatment at the IC90 in JPCM5 cells show reduced growth by 50% after 5 h. One representative biological replicate (with internal
technical replicates) is shown. (c) Relative reactive oxygen species (ROS) production was lower in all resistant lines compared to JPCM5 cells. *Denotes a p value of <0.05. An
average of at least three independent biological replicates is shown, with error bars depicting the standard error of the mean. (d) Microscopy images of cellular changes after
5 h of miltefosine treatment at IC90. JPCM5 wild-type (d), MF200 (h), SbIII2000.2 (s), and untreated wild-type (j).
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type JPCM5 was also observed (Fig. 2b) and this was statistically
significant (p < 0.05 in a Student’s t-test) at 45 min and 1 h. Miltefo-
sine transport into Leishmania is known to involve a transporter
complex of the miltefosine transporter (MT, LinJ.13.1590) and
ROS3 (LinJ.32.1040) (Pérez-Victoria et al., 2003a,b, 2006b). The
MT is frequently mutated in miltefosine resistance, although the
mutations seen have been very variable (Coelho et al., 2012). We
cloned and sequenced the MT gene from the wild-type and the
MF200 and SbIII2000.2 resistant lines. We found no SNP in the
wild-type gene, but found a G to A transition in the MT gene of
MF200, leading to a G821D amino acid change. This mutation is
not in a transmembrane domain or in the ATPase domain. Surpris-
ingly, therewere also twomutations in the SbIII2000.2MT (G26A in
the DNA sequence leading to an R9H in the amino acid sequence
and C222T which is silent at the amino acid level), which may ac-
count for the reduced levels of uptake seen.
The uptake of miltefosine in the wild-type cell line is relatively
rapid, with significant uptake seen after 1 h. Since there is not
much ROS production at this time point (Fig. 1c), the initial target
of miltefosine should be indicated by the metabolite profile at the
first time point at 1.25 h in the wild-type cells. There are 60 metab-
olites with altered levels at this time point in the wild-type cell
line, 28 in the resistant line and just three in the SbIII resistant line
(Supplementary Table 2). In the wild-type cell line, a metabolite
putatively identified as ovothiol A disulphide is the metabolite that
shows the largest reduction in levels between the two time points,decreasing to 6.9% of the levels in untreated cells after 1.25 h (Sup-
plementary Table 2). This suggests that the thiol is being reduced
in preparation for the larger burst of oxidative stress to come.
Other metabolites showing altered levels in these cells included a
wide range of metabolites putatively identified as hormones, sug-
ars, acids and lipids. One lipid in particular (with a mass of
453.3219) was increased 1629 fold upon miltefosine introduction.
This same increase was seen in the SbIII resistant line and to a
much lesser extent in the miltefosine resistant line (Supplemen-
tary Table 1). This intracellular lipid relates to a formate (CH2O2)
adduct of miltefosine and is therefore unlikely to be parasite de-
rived, but instead derives from the drug itself, confirming the up-
take of miltefosine. No metabolites could be found that would
relate to a parasite-derived processing of miltefosine and the drug
itself was unaltered from thin layer chromatography analysis (data
not shown).
The altered metabolite profiles do not reveal an obvious pri-
mary metabolic target of miltefosine. This may mean that the ini-
tial target of miltefosine is not metabolic or that the metabolites
affected by the target inhibition were not well ionised using this
method.
3.2. The mode of action of miltefosine involves internal lipid
remodelling
It was immediately evident that at the final 5 h time point in the
wild-type cell line treated with miltefosine, many metabolites that
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reduction in abundance (Supplementary Table 1). The cells ap-
peared slightly smaller and more spherical after 5 h in drug
(Fig. 1d), but the cell volume was not systematically measured.
The drop in metabolite abundance could be due to a decrease in
cell size but is muchmore likely to be due to cell leakage. We chose
to analyse which metabolites were altered at the penultimate,
3.75 h time point, as the majority of metabolites (90%) were stable
until this time point, indicating that the cell volume was not signif-
icantly altered. There was also no alteration in the membrane com-
position at this time point and no increase in lyso-phospholipids
(all indicative that the membrane was not compromised). The
growth curves corroborate this point (Fig. 1b).
There were 87 metabolites having a p value of <0.05 from a Stu-
dent’s t-test and a fold change of >2 at the penultimate time point
in the wild-type cell line (Supplementary Table 3). Some of these
metabolites did not show an obvious upwards or downwards trend
and seemed to be very variable between the time points, but there
was an upwards trend in many alkane fragments, which may be re-
lated to lipid metabolism (Fig. 3a). These metabolites were small
saturated alcohols and carboxylates on alkane chains of between
four and 10 carbons. Ethanolamine phosphate and putative 5-
aminopentanoate were the only metabolites in this group to de-
crease over the time course. Metabolites related to sugars and
bases also showed changes in abundance with a marked increase
in putative glucosamine phosphate (Fig. 3b). The increase in puta-
tive glucosamine phosphate and the lipids are consistent with an
increased lipid turnover, which would release alkane fragments
and sugar amines. Miltefosine induces ROS at this penultimate
time point in the wild-type cells (Fig. 1c) and ROS have been
known to attack native membrane phospholipids. However, a lipi-
domic analysis of phospholipids did not reveal any significant
changes after 3.75 h of miltefosine treatment (Fig. 4), only the up-
take of unmetabolised miltefosine (data not shown).
Not all sugars showed an increase in abundance and some, such
as D-glucose 6-phosphate, D-mannonate, 2-deoxy-L-arabinose and1-deoxy-D-xyulose showed a decreasing trend. It is difficult to con-
clusively identify five and six carbon sugars after separation by the
ZIC-HILIC column, as these species have many stereoisomers,
which do not separate efficiently and therefore have the same ex-
act mass and very similar retention times.
The changes in internal lipid fragments (Fig. 3a), sugars
(Fig. 3b), DNA, thiols, peptides (Fig. 3c) and others (Fig. 3d) ob-
served in the wild-type cells were not observed in the MF200 line
(Fig. 3, right insets). The SbIII resistant line, however, showedmany
of the same changes as the wild-type cells in terms of increased al-
kane fragments (Fig. 3a left inset), although to a lesser extent and
without the metabolite leakage at 5 h. The sugars, DNA fragments,
thiols, peptides and others (Fig. 3b–d, left insets) did not show such
marked changes as in the wild-type line.3.3. Evidence of cell stresses
ROS have previously been shown to attack DNA, causing DNA
laddering (Moreira et al., 2011), which could result in the release
of nucleotide fragments as seen in Fig. 3c. The release of nucleases
may also be responsible for these fragments if the mitochondrial
outer membrane was compromised. Some putative dipeptides
are seen to increase in abundance (Fig. 3d), which could be a result
of protein breakdown, but as there are only two dipeptide species
represented, this seems unlikely. Putative trypanothione disul-
phide decreases slightly in abundance over the time course
(Fig. 3d), whereas putative glutathione disulphide levels decrease
at the 1.25 h time point before recovering and increasing signifi-
cantly towards the 3.75 h time point (Supplementary Table 1). Try-
panothione disulphide is a dithiol-polyamine constructed using
two glutathione molecules conjugated via a spermidine linker
(Fairlamb et al., 1985). The decrease in trypanothione may result
from the release of glutathione to compensate for the shock de-
crease at the first time point. The spermidine peak was automati-
cally rejected by the IDEOM software in this dataset because the
ion was detected with a shoulder peak (two overlapping peaks
with the same mass), but the spermidine standard run before the
dataset confirms that this peak is in fact spermidine. The levels
of spermidine appeared to show an initial decrease followed by a
recovery (Supplementary Table 1, ‘‘rejected’’ tab), therefore if try-
panothione is recycled to produce more glutathione, then the re-
leased spermidine must also be used for another purpose as
spermidine’s levels are not in accordance with those for glutathi-
one. Unfortunately, the oxidation state of glutathione and trypano-
thione cannot be ascertained in this experiment as the method
used results in the oxidation of these thiols. Ovothiol A and Ovoth-
iol A disulphide, two other important thiols, fluctuated over the
time course. Thiamin monophosphate also has a sulphur group
and was significantly increased during miltefosine treatment
(Fig. 3d). These cell stresses were not seen by either of the resistant
lines (Fig. 3, insets), except for the decrease in trypanothione disul-
phide seen in the SbIII resistant line (to 59% after 5 h), which is
similar to the decrease in wild-type cells (to 50% after 5 h)
(Fig. 3d and Supplementary Table 3).4. Discussion
Metabolomics studies are rare in parasitic protozoa, but have
huge potential use to determine the MOA of the often very old
and toxic drugs. A knowledge of the MOA of a compound is para-
mount to rational drug design to improve efficacy and to predict
and reduce toxicity. Mechanisms of resistance to the compound
can also be predicted if the MOA is known and synergistic com-
pounds can be found that would reduce the chances of resistance
developing.
Fig. 3. Changes in the intensity of metabolites associated with miltefosine action. Metabolite changes in the wild-type line are sorted into groups for (a) alkane fragments, (b)
sugars, (c) DNA fragments, thiols and peptides and (d) others. Inset graphs show average ratio changes in the SbIII2000.2 (top left) or MF200 (top right). To determine whether
the metabolites that showed an upwards trend in the wild-type line also showed an upwards trend in the resistant lines an average of all the metabolites that increased in
wild-type was taken for each resistant line. The same was done for metabolites that showed a downward trend in the wild-type line. (d) In inset graphs shows the average
ratio of metabolites that increased in wild-type cells for each metabolite grouping. (s) In inset graphs shows the average ratio of metabolites that decreased in the wild-type
cells. The scales are conserved in the inset graphs. An average of three replicates is shown and relative standard deviation for each point was below 0.5.
I.M. Vincent et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 20–27 25The MOA of miltefosine is undetermined, but there are three
schools of thought in circulation: Akt inhibition leading to apopto-
sis, modulation of macrophage responses and changes to mem-
brane phospholipid architecture. Here we show changes in the
internal metabolome of Leishmania promastigotes over time in re-
sponse to the xenobiotic miltefosine using LC–MS. We were also
able to show accumulation of miltefosine in the wild-type cell line
and show that the drug is not accumulated in the MF200 miltefo-
sine resistant cell line. This was confirmed biochemically and SNPs
were detected in the transporter for miltefosine that may cause
this reduction in miltefosine accumulation. We were surprised to
see a reduction in miltefosine accumulation in the Sb2000.2 mu-
tant during the first 60 min (Fig. 2b) and even more surprised by
the presence of SNPs in the MT gene for the SbIII2000.2 mutant.
Sequencing of the MT gene in other antimony resistant mutants
suggests that this is a rare event, but nevertheless the demonstra-
tion that MT can be mutated in an antimony resistant mutant
opens the possibility for multidrug resistance.
Miltefosine treatment of wild-type promastigotes alters
approximately 10% of the metabolome after 3.75 h, with many of
the changes relating to an increase in short alkanes and sugars.
The changes seen are synchronised with the production of reactive
oxygen species. Membrane-incorporated lipids were not signifi-
cantly altered in our experiments. This contradicts earlier research
(Rakotomanga et al., 2004, 2007), but since the earlier published
work was done with a lower drug concentration and for a longer
period of time, their work may actually have been showing an
adaptive response to miltefosine (Rakotomanga et al., 2007). Signs
of DNA damage were also detected as were changes to the levels ofsome thiols and polyamines (Fig. 3). Exogenous spermidine has
previously been shown to increase the life span of yeast, nema-
todes, flies and human immune cells in culture (Eisenberg et al.,
2009). The mechanism for this spermidine-induced death delay
is not known, but it has been suggested that it may involve remod-
elling of chromatin and upregulation of autophagy, increasing
resistance to oxidative stress (Eisenberg et al., 2009). When sper-
midine levels in Trypanosoma cruzi, a related kinetoplastid, are re-
duced, lipid peroxidation was shown to be increased. Spermine, a
related polyamine not found in Leishmania (due to the lack of a
spermine synthase) has also been observed to be effective at lipid
peroxidation rescue (Hernández et al., 2006). The putative early re-
lease of spermidine (Supplementary Table 1) may help the cell to
deal with miltefosine exposure.
After 5 h of miltefosine treatment on wild-type cells, there were
depleted levels of most metabolites, which would indicate that the
cells’ outer membrane integrity had become compromised and
metabolites were escaping during cell death. This may be due to
the release of lipases following mitochondrial stress. The miltefo-
sine resistant line did not accumulate miltefosine at all, did not dis-
play a ROS induction and did not show the alterations to the lipids,
sugars and nucleobases that the wild-type line did.
It must be noted that all studies of miltefosine mode of action to
date have been performed on promastigote cells so caution must
be taken when applying the results to the parasite in general. How-
ever, metabolomic studies on intracellular parasites are problem-
atic due to the generic nature of the measured metabolites and
the inability to determine whether they are parasite or host de-
rived. These data suggest that the mode of action of miltefosine
Fig. 4. There are no significant changes to the membrane lipids after miltefosine treatment. Negative ion ES-MS survey scans (600–1000 m/z) of total lipid extracts from L.
infantum in the (a) absence or (b) presence of miltefosine (20.6 lM) for 3.75 h. Positive ion ES-MS survey scans (600–1000m/z) of total lipid extracts from L. infantum in the (c)
absence or (d) presence of miltefosine for 3.75 h. PEs: phosphoethanolamines, IPCs: inositol phosphocholines and PIs: phosphoinositols. An example of one of three
independent biological replicates (which showed similar profiles) is shown.
26 I.M. Vincent et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 20–27in promastigote Leishmania is due to cell lysis preceded by altera-
tions to internal lipid metabolism causing increases in alkanes,
sugars and nucleotides. These alterations probably occur through
the induction of reactive oxygen species. Understanding the mode
of action of miltefosine is useful to help to develop effective com-
bination therapies to ensure that resistance to any of the drugs is
much less likely. Combining miltefosine with a drug that depreci-
ates the cell’s capacity to deal with ROS, such as the polyamine
pathway inhibitor, eflornithine, is likely to be synergistic and could
be considered for therapeutic use.Conflicts of interest
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